Lurie Children's Hospital of Chicago (LCH) CRS
Chicago, Illinois 60614-3393
0 studies enrolling now · 11 studies all time
What they study most
HIV Infection, HIV Infections, Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus Infections
Studies at this site
- More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents — Completed
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy — Completed
- Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age — Stopped early
- The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age — Completed
- Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age — Completed
- Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age — Completed
- Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection — Completed
- Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents — Completed
- Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection — Completed
- Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children — Completed
- Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age — Completed